Table 4. Clinical trials of target therapies in second line mesothelioma.
| First author | Phase | Drugs | Patients | RR (%) | mTTP/mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
| Krug LM (34) | III | Vorinostat | 329 | − | 1.5 | 7.2 |
| BSC | 332 | − | 1.4 | 6.3 | ||
| Gregorc V (35) | III | NGR-hTNF | 200 | − | − | 8.4 |
| BSC | 200 | − | − | 7.9 | ||
| Buikhuisen WA (36) | III | Thalidomide | 111 | − | 3.6 | 10.6 |
| BSC | 111 | − | 3.5 | 12.9 | ||
| Ou SH (37) | II | Everolimus | 59 | 2 | 2.8 | 6.3 |
| Maron SB (38) | II | ARQ197 | 18 | 0 | 1.9 | 12.2 |
| Wheatley-Price P (39) | II | PF-03446962 | 17 | 0 | 1.7 | − |
| Nowak AK (40) | II | BNC105P | 30 | 4 | 1.6 | 8.2 |
| Dubey S (41) | II | Sorafenib | 51 | 6 | 3.6 | 9.7 |
| Fennel DA (42) | II | Bortezomib | 23 | 5 | 2.1 | 5.8 |
| Nowak AK (43) | II | Sunitinib | 53 | 12 | 3.5 | 6.1 |
| Dudek AZ (44) | II | Dasatinib | 46 | 5 | 2.0 | 6.0 |
| Papa S (45) | II | Sorafenib | 53 | 6 | 5.1 | 9.0 |
| Laurie SA (46) | II | Sunitinib | 17 | 0 | 2.8 | 8.3 |
| Garland LL (47) | II | Cediranib | 54 | 9 | 2.6 | 9.5 |
| Gregorc V (48) | II | NGR-hTNF | 43 | 2 | 2.8 | 12.1 |
| Ramalingam SS (49) | II | Belinostat | 13 | 0 | 1.0 | 5.0 |
| Jakerman DM (50) | II | Erlotinib bevacizumab | 21 | 0 | 2.2 | 5.8 |
RR, response rate; mTTP, median time to progression; mPFS, median progression free survival; mOS, median overall survival.